At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 326 enrolled
Drug / intervention
CTP-692 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of CTP-692 as an Adjunctive Treatment in Adult Patients With Schizophrenia
In Brief
A Phase 2 clinical trial evaluating CTP-692 and Placebo for Schizophrenia. Completed, enrolled 326 participants across 26 sites.
Detailed Summary
The objective of this study is to assess the safety and efficacy of 3 different doses of CTP-692 administered once daily (QD) for 12 weeks to adult participants with schizophrenia on stable dopaminergic antipsychotic medication.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
CollaboratorsCognitive Research Corporation
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartNov 2019
Primary CompletionDec 2020
TodayJul 2026
First PostedNov 12, 2019
Enrollment StartNov 26, 2019
Primary CompletionDec 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 6.6 years ago
Interventions
CTP-692drug
Administered as powder for oral solution.
Placebodrug
Administered as powder for oral solution.